ECHANISMS contributing to the development of cerebral vasospasm after SAH have not been completely uncovered despite recent scientific progress in this area. The disturbance of the networklike interaction between NO and ET-1 in the cerebrovasculature, however, is assumed to play a major role in the pathophysiological sequence leading to cerebral vasospasm. 8, 9, 11 In this network ET-1 represents the contractile partner. It is a 21-amino acid polypeptide that was first isolated from porcine endothelial cells. 33 The vasomotor effects of ET-1 are mediated by activation of specific receptors known as ET A 1 and ET B .
tinguish it from a smooth-muscle subtype of the ET B receptor found in some peripheral blood vessels. 7 Activation of the latter receptor, which has been named ET B2 , 2 mediates contraction. Both the ET B1 and ET B2 receptors are encoded by the same gene, and therefore they may differ in localization and function rather than in molecular configuration. 7 The presence of a contractile ET B receptor has not yet been proved in the cerebrovasculature under physiological conditions, 21 but evidence has been presented in favor of its expression in cerebral vessels after experimental stroke 26 and SAH. 12, 34 The existence of the vasodilatory ET B1 receptor in the cerebrovasculature, however, is not a subject of debate. The vasodilator effect is coupled to NO production, 14, 22 but is often masked in cerebral arteries because of the simultaneously occurring activation of functionally predominant ET A receptor-mediated contraction. 10, 22, 32 Accordingly, interference with the ET system for the treatment of cerebral vasospasm after SAH should have as its goal the prevention of ET A receptor-mediated vasoconstriction without impairment of the ET B1 receptor-dependent dilatory effect. Therefore, a highly ET A receptor-selective antagonist seems to be the most suitable approach for this indication.
Clazosentan (previously known as Ro 61-1790) is a selective ET A receptor antagonist with a high affinity to the ET A receptor 17 (also see Part I of our study 31 ), although some affinity to the ET B receptor has been considered, based on findings of competition binding assays. 17 Clazosentan represents the first pharmacological compound to be successful in the prevention and reversal of cerebral vasospasm in an initial clinical trial including 32 patients. 28 This remarkable effect of clazosentan on cerebral vasospasm is most probably caused by antagonism at the cerebrovascular ET A receptor, but a potential interaction with the cerebrovascular ET B1 receptor may also occur. Such an interaction may at least partly attenuate the therapeutic effect and may thus represent an undesired side effect due to the pharmaclogical properties of the antagonist.
The aim of the present study was, therefore, to characterize the interaction of clazosentan with ET B1 receptor-mediated relaxation in the cerebrovasculature. This study is important because it will offer a description of the actual T receptor selectivity of clazosentan in its target organ and may help improve our basic knowledge, leading to well-tailored compounds for the treatment of cerebral vasospasm after SAH.
Materials and Methods

Tissue Preparation
The experiments were performed using BA ring segments from male Sprague-Dawley rats, each of which weighed between 250 and 340 g. The procedure followed to obtain the BA segments is described in detail in Part I 31 and will only be briefly summarized here. The animals were anesthetized with CO 2 and then killed by exsanguination from the external carotid arteries. The brain together with the cerebral vessels were excised and immersed in cold modified Krebs-Högestätt solution. The BA was dissected meticulously with the aid of a binocular microscope and cut into four-ring segments, each measuring 2 mm in length. The segments were transferred to an organ bath and mounted over two L-shaped stainless-steel wires (70 m diameter) for the measurement of isometric force. The organ baths were filled with modified Krebs-Högestätt solution and continuously bubbled with a humidified gas mixture of 95% O 2 /5% CO 2 , resulting in a pH of approximately 7.35 at the end of the adaptation procedure.
Experimental Protocol
After preparation of the segments, the temperature in the organ baths was gradually increased to 37˚C. During this adaptation period of 60 minutes, the segments were repeatedly stretched to adjust a resting tension of 3 to 4 mN. Contraction of segments was induced by 124 mM K ϩ Krebs solution (Krebs-Högestätt solution with an equimolar exchange of NaCl by KCl); this was used as a reference contraction following the adaptation period. Segments reaching less than 2.5 mN in the reference contraction were discarded. The functional integrity of the endothelium was tested by application of acetylcholine (10-5 M) after a precontraction had been induced with 5-hydroxytryptamine (10-5 M). Segments yielding a relaxation of more than 30% of the precontraction were considered to possess a functionally intact endothelium (Eϩ), as demonstrated previously by correlation of functional data with electron microscopy investigations. 23 Only Eϩ segments were included in the present experiments. Concentration effect curves for the ET B -selective agonist sarafotoxin S6c (concentration range 10 Ϫ12 to 10 Ϫ7 M), ET-1 (10 Ϫ12 to 10 Ϫ7 M), and big ET-1 (10 Ϫ12 to 10 Ϫ6 M) were constructed by cumulative application of each compound on the top of a pharmacological tone of at least 1 mN induced by PGF 2␣ (10 Ϫ5 M). Only one CEC was constructed in each segment because of tachyphylaxis. In experiments in which clazosentan (10 Ϫ9 to 10 Ϫ6 M) was used, the segments were preincubated for at least 30 minutes before sarafotoxin S6c, ET-1, or big ET-1 was applied.
Compounds and Solvents
Endothelin-1 (1-21 amino acids) and human big ET-1 (1-38 amino acids) were purchased from Calbiochem-Novabiochem (Bad Soden, Germany); sarafotoxin S6c from Alexis (Gruenberg, Germany); and acetylcholine, 5-hydroxytryptamine, and PGF 2␣ from Sigma-Aldrich (Schnelldorf, Germany). Clazosentan (Ro 61-1790) was kindly provided by V. Breu (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland). All compounds were dissolved in distilled water. Stock solutions were made fresh on the day of each experiment and appropriately diluted before application.
Analysis of Results
Contraction was measured in millinewton force. Relaxation was calculated as the percentage of the decrease in the corresponding precontraction. In the presence of clazosentan the relaxation induced by ET-1 or big ET-1 occurred in a biphasic time course, as reported previously 25 and demonstrated in Fig. 1 . This time course starts with an initial, partly transient relaxation, which is mediated by the ET B receptor. 23 This relaxation is followed by a repeated increase in vessel tone ( Fig. 1 ). The maximum decrease in tone was termed "peak" and the first stable level after the repeated increase was designated "plateau." 23 The second part of this biphasic vasomotor effect is variable and no data exist to support its dependence on the ET B receptor. Therefore, the peak after application of sarafotoxin S6c, ET-1, or big ET-1, which reflects the maximum level of the ET B receptor-mediated relaxant effect most closely, was evaluated in the present investigation.
For each individual CEC we determined the E max that was obtained and we also performed a linear regression analysis after logarithmic transformation of concentrations above and below the level of the EC 50 to calculate the negative decadic logarithms of the EC 50 , the pD 2 . For a comparison of the CECs for sarafotoxin S6c-induced relaxation in the presence of clazosentan with the control curve, the shift of the curves was calculated on the level of the EC 50 by dividing the EC 50 of the CECs in the presence of clazosentan by the EC 50 of the control curve. In addition the slopes of the CECs around the EC 50 were determined using linear regression analysis.
For the statistical analysis we used a one-way analysis of variance followed by the Tukey test for a post hoc comparison of mean values. To characterize the inhibitory potency of clazosentan, the pA 2 value was determined using the method of van Rossum. 29 All values in the text, tables, and figures are given as means Ϯ SEMs. A probability value less than 0.05 was considered significant.
Results
Effect of Clazosentan on Relaxation of BA Segments Induced by Sarafotoxin S6c
Cumulative application of sarafotoxin S6c on precontracted segments resulted in a dose-dependent relaxation (Fig. 2) . In the presence of low concentrations of clazosentan (10 Ϫ9 and 10 Ϫ8 M), no significant changes in the CEC occurred (Table 1 ). In the presence of higher concentrations of clazosentan (10 Ϫ7 and 10 Ϫ6 M), however, the CEC of sarafotoxin S6c-induced relaxation was shifted to the right without a significant effect on the E max or slope (Table 1 and Fig. 1 ). This observation is compatible with a competitive inhibition of ET B receptor-mediated relaxation by clazosentan. The pA 2 was estimated to be 7.1, which is approximately 63-fold lower than the respective value obtained for the ET-1-induced ET A receptor-mediated contraction in EϪ BA segments (see Part I 31 ).
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Effect of Clazosentan on Relaxation of BA Segments Induced by ET-1 and Big ET-1
In the absence of clazosentan ET-1-induced a small transient relaxation only in precontracted segments. Therefore, a reliable pD 2 value for this relaxation could not be calculated. In the presence of high concentrations of clazosentan (10 Ϫ7 and 10 Ϫ6 M), however, application of ET-1 resulted in a reproducible biphasic response of vessel tone consisting of a peak and a plateau (Fig. 1A) . In either case the maximum relaxant effect (E max ) was virtually identical and comparable with the E max values yielded by sarafotoxin S6c (Tables 1 and 2 ). The CEC for ET-1-induced relaxation in the presence of clazosentan (10 Ϫ6 M) was significantly shifted to the right by a factor of 6.1 compared with the CEC in the presence of 10 Ϫ7 M clazosentan (Fig. 3) . The slopes of these CECs did not differ significantly, which was compatible with a competitive inhibition of relaxation by clazosentan in the higher concentration (10 Ϫ6 M). Assuming that ET B receptor-dependent relaxation is unmasked but not yet markedly inhibited by 10 Ϫ7 M clazosentan, a pA 2 of 6.7 could be estimated by the shift between both these CECs determined using the method of van Rossum. 29 In contrast to ET-1, a significant relaxation for big ET-1 was observed in the absence of clazosentan in accordance with previous results. 25 In the presence of clazosentan (10 Ϫ7 M) the CEC for big ET-1-induced relaxation was shifted to the right and the E max was markedly enhanced compared with the control curve (Fig. 4) ; however, neither effect reached statistical significance. In the presence of 10 Ϫ6 M clazosentan, however, the CEC was significantly shifted to the right compared with the control (Fig. 4 and Table 2 ). These observations further support the assumption that the ET B1 receptor-mediated relaxation is unmasked but not or only slightly inhibited in the presence of 10 Ϫ7 M clazosentan, although it is inhibited in the presence of higher concentrations. The shift in CECs for big ET-1-induced relaxation caused by 10 Ϫ6 M clazosentan was 4.3 compared with the CEC obtained in the presence of 10 Ϫ7 M clazosentan. The slopes of these CECs showed a slight tendency to increase with higher concentrations of the antagonist; however, this trend was not significant. The pA 2 , which was estimated in the same manner as for ET-1, that is, by a comparison of CECs in the presence of 10 Ϫ7 M and 10 Ϫ6 M clazosentan, had a value of 6.5, which was very similar to the value found for ET-1.
Discussion
The present data indicate a competitive inhibition of ET B receptor-mediated relaxation by clazosentan in its potential target organ, the cerebrovasculature. Although assessed as a highly selective high-affinity ET A receptor antagonist, 17 its inhibitory effect on the ET B receptor was observed in a concentration range that may be reached in the plasma of patients during treatment of cerebral vasospasm (V Breu, personal communication, 2004). This action could thus attenuate the antivasospastic efficacy of clazosentan. Therefore, the relevance of its interaction with the ET B receptor justifies basic and clinical investigations to optimize the therapeutic regimen for this compound.
In the present investigation, the inhibitory effect of clazosentan on the ET B1 receptor-mediated relaxation of the rat BA was comparable to findings of functional studies on the ET B2 receptor-mediated contraction of the isolated rat trachea and to those of competition binding assays. In those studies, pA 2 values between 6.7 and 5.5 were obtained. 17 The ET A receptor selectivity of clazosentan was derived from the markedly higher affinity of this compound at the ET A receptor site-approximately 100 to 15,000-fold higher than that found at the ET B receptor. 17 This wide range of affinity/selectivity difference may be caused by different structures of ET receptors in different tissues and a variable second messenger coupling of receptor subtypes. 6 The present data demonstrate an ET A receptor selectivity that is little less than two logarithmic units, underlining the need to use the specific target organ for the characterization of a potentially useful drug.
To separate out the contraction-and relaxation-inducing actions of ET-1, activation of the ET A receptor must be antagonized as described previously. 10 In the present study, this was achieved with clazosentan, resulting in a biphasic response of the precontracted arteries to applications of ET-1 and big ET-1. The first part of this response is a relaxation, which in most instances was not sustained. This relaxation appears to be due to activation of ET B receptors on the endothelial cells and release of NO because it can be abolished by the ET B receptor antagonist BQ788 and by an inhibitor of NO synthase, respectively. 22 The second part of the response is a partial or complete recovery of tone or even a further contraction. The mechanisms underlying the second part of the response seem to be more complex, and several components may be involved including the following: 1) a spontaneous attenuation of the relaxant response due to consumption of L-arginine; 2) a tachyphylaxis-like response of smooth muscle soluble guanylyl cyclase; 9 and 3) an increasing activation of the ET A receptor with increasing concentrations of ET-1 or big ET-1. Therefore, we chose to analyze the peak value of the initial relaxation exclusively because this appears to reflect ET B receptor activation most reliably.
Under physiological conditions, the ET-1-induced constriction of cerebral blood vessels is mediated by activation of the ET A receptor, 9, 21 in contrast to some peripheral vascular beds where an ET B2 receptor-dependent vasoconstriction was shown. 19 Under pathological conditions, however, an ET B receptor-mediated component may emerge in cerebral arteries. In a previously published study, experimental cerebral vasospasm could be attenuated by long-term treatment with selective ET B receptor antagonists. 34 This effect was attributed by the authors to an inhibition of the ET B receptormediated release of ET-1. 34 This hypothesis obviously does not presuppose the presence of a contractile ET B receptor in the cerebrovasculature. More recently, evidence for an upregulation of the level of ET B receptors in the cerebrovasculature was presented based on gene expression studies performed after experimental SAH. 12, 13, 18 Nevertheless, the
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Characterization of clazosentan on the ET B receptor 1111 In experimental cerebral ischemia in rats administration of an ET B receptor antagonist increased the infarction volume, 5 and in ET B receptor-deficient animals neuronal damage was augmented. 25 These data may be taken to indicate a neuroprotective action on the part of the ET B receptor after cerebral ischemia. This neuroprotection has been related to a vascular effect-ET B1 receptor-mediated vasodilation 10, 14, 16, 22 -resulting in maintenance or improvement of CBF. Nevertheless, there is also evidence for an upregulation of ET B expression and a contractile effect of sarafotoxin S6c in the deendothelialized rat middle cerebral artery after ischemia-reperfusion injury. 26 Such a contractile effect cannot be observed in segments carrying an intact endothelium (unpublished observations), however, thus challenging the concept of an ET B receptor-mediated increase in vascular tone. Therefore, treatment of impaired CBF under pathological conditions should inhibit ET A receptor-mediated contraction without impairing ET B1 receptor-dependent vasodilatory action. Accordingly, a successful prevention or treatment of experimentally induced cerebral vasospasm following SAH was widely observed by selective ET A receptor antagonists such as clazosentan 4, 17, 30 and by mixed receptor antagonists displaying a high affinity to the ET A receptor. 4, 30 The plasma concentrations of clazosentan in patients treated for the prevention or reversal of cerebral vasospasm were in the range of 5 ϫ 10 Ϫ7 to 10 Ϫ6 M (V Breu, personal communication, 2004). The present results demonstrate that in this concentration range an ET B receptor antagonistic effect of clazosentan has to be expected. If this holds true, the therapeutic efficacy of clazosentan may be limited due to partial inhibition of the relaxation induced by stimulation of the ET B1 receptor. The cerebrovascular effects of ET-1, however, are thought to be elicited from the adventitial side of the cerebral blood vessels, and an increase in the concentration of ET-1 in CSF has been related to the development of cerebral vasospasm in some clinical studies. 7, 24, 27 Accordingly, the penetration of clazosentan into the CSF and its actual concentration in this compartment appear to be important issues. Previous investigations 3, 17 have provided evidence in favor of the ability of clazosentan to cross the blood-brain barrier. In view of the efficacy of clazosentan to prevent and even reverse cerebral vasospasm in patients, 28 our findings indicate a level of clazosentan in the CSF that is sufficient for inhibition of the ET A receptor. Whether clazosentan reaches its optimal concentration in the CSF cannot be judged yet. Nevertheless, once data on the actual clazosentan content in the CSF become available, the data of the present study will provide the basis to assess and possibly optimize dosing to the maximal therapeutic effect attainable. Ϫ7 M clazosentan is apart from the E max , which is markedly enhanced but not significantly different from the control curve. In the presence of 10 Ϫ6 M clazosentan the CEC is shifted to the right significantly, indicating a competitive inhibition of ET B receptor-dependent relaxation. Values are expressed as means Ϯ SEMs. * p Ͻ 0.05 compared with control.
